At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 325 enrolled
Drug / intervention
BMS-986020 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis
In Brief
A Phase 2 clinical trial evaluating BMS-986020 and Placebo matching with BMS-986020 for Idiopathic Pulmonary Fibrosis. Completed, enrolled 325 participants across 72 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine if study drug (BMS-986020) dose of 600 mg once daily or 600 mg twice daily for 26 weeks compared with placebo will reduce the decline in forced vital capacity (FVC) and will be well tolerated in subjects with idiopathic pulmonary fibrosis (IPF).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsIdiopathic Pulmonary Fibrosis
CountriesAustralia, Chile, Colombia, Mexico, Peru, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedJan 2013
Enrollment StartJan 2013
Primary CompletionFeb 2016
TodayJul 2026
First PostedJan 11, 2013
Enrollment StartJan 31, 2013
Primary CompletionFeb 29, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 13.5 years ago
Interventions
BMS-986020drug
Placebo matching with BMS-986020drug